Insurers put in bid for biosimilar naming

Share this article:

Brand-name marketers may support unique names for biosimilar products, but the Wall Street Journal reports an array of pharmacies, health insurers and unions are urging the FDA to require biosimilars share the same name as the drugs they imitate, just like generics and branded drugs do.

The no-unique-name coalition says having multiple names for biosimilars that refer to the same branded drug will confuse doctors and patients. They also say multiple names for similarly indicated drugs could increase the risk of prescription errors.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions